Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citalopram + donepezil is a combination of two approved small molecule drugs, each with distinct mechanisms of action. Citalopram is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat depression by increasing serotonin levels in the brain through inhibition of its reuptake. Donepezil is an acetylcholinesterase inhibitor indicated for the symptomatic treatment of Alzheimer's disease and other dementias; it works by inhibiting the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. This combination may be considered in patients with comorbid depression and dementia but carries risks due to overlapping side effects, particularly QT interval prolongation[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + donepezil.